ONTOLOGY REPORT - ANNOTATIONS
| Term: | (+)-alpha-tocopherol |
|
| Accession: | CHEBI:18145
|
browse the term
|
| Definition: | An alpha-tocopherol that has formula C29H50O2. |
| Synonyms: | exact_synonym: | (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol |
| | related_synonym: | (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; (2R,4'R,8'R)-alpha-tocopherol; (R,R,R)-alpha-tocopherol; 5,7,8-trimethyltocol; C29H50O2; CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1; InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1; InChIKey=GVJHHUAWPYXKBD-IEOSBIPESA-N; Vitamin E; d-alpha-tocopherol |
| | alt_id: | CHEBI:10336; CHEBI:12343; CHEBI:46509 |
| | xref_casrn: | 59-02-9 |
| | xref: | Beilstein:5300493 "Beilstein Registry Number"; Beilstein:94012 "Beilstein Registry Number"; ChEMBL:103345 "ChEMBL COMPOUND"; ChemIDplus:59-02-9 "CAS Registry Number"; DrugBank:DB00163 "DrugBank"; KEGG COMPOUND:59-02-9 "CAS Registry Number"; KEGG COMPOUND:C02477 "KEGG COMPOUND"; LIPID MAPS:LMPR02020000 "LIPID MAPS instance"; LIPID MAPS:LMPR02020001 "LIPID MAPS instance" |
| | xref_mesh: | MESH:D024502 |
| | xref: | PDBeChem:VIV "PDBeChem" |
| | cyclic_relationship: | is_enantiomer_of CHEBI:46430 |
|
|
(+)-alpha-tocopherol
|
| G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
|
multiple interactions |
EXP |
8 |
57,044,478 |
57,072,970 |
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Acvrl1 |
activin A receptor type II-like 1 |
|
increases expression |
EXP |
7 |
139,873,596 |
139,884,675 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Akr1b1 |
aldo-keto reductase family 1, member B1 (aldose reductase) |
|
increases expression |
EXP |
4 |
61,645,438 |
61,659,530 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alad |
aminolevulinate dehydratase |
|
multiple interactions |
ISO |
5 |
79,505,645 |
79,515,983 |
RGD:6480464 |
CTD |
| G |
Alas1 |
aminolevulinate, delta-, synthase 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Apoa1 |
apolipoprotein A-I |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Apoa1 |
apolipoprotein A-I |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Apob |
apolipoprotein B |
|
multiple interactions |
ISO |
6 |
31,508,060 |
31,548,083 |
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Atf2 |
activating transcription factor 2 |
|
multiple interactions |
ISO |
3 |
56,403,676 |
56,496,473 |
RGD:6480464 |
CTD |
| G |
Bace1 |
beta-site APP cleaving enzyme 1 |
|
multiple interactions |
ISO |
8 |
48,817,824 |
48,839,681 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
decreases expression |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Canx |
calnexin |
|
affects localization |
EXP |
10 |
35,850,944 |
35,883,494 |
RGD:6480464 |
CTD |
| G |
Canx |
calnexin |
|
increases expression |
EXP |
10 |
35,850,944 |
35,883,494 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
decreases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases cleavage |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases cleavage |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases expression |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
affects expression |
EXP |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cd36 |
CD36 molecule (thrombospondin receptor) |
|
multiple interactions |
EXP |
4 |
13,471,878 |
13,525,620 |
RGD:6480464 |
CTD |
| G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
|
multiple interactions |
ISO |
4 |
43,874,852 |
44,041,870 |
RGD:6480464 |
CTD |
| G |
Cldn2 |
claudin 2 |
|
multiple interactions |
EXP |
X |
127,538,685 |
127,549,019 |
RGD:6480464 |
CTD |
| G |
Crabp2 |
cellular retinoic acid binding protein 2 |
|
multiple interactions |
ISO |
2 |
180,029,801 |
180,034,147 |
RGD:6480464 |
CTD |
| G |
Crp |
C-reactive protein, pentraxin-related |
|
multiple interactions |
ISO |
13 |
88,702,243 |
88,703,153 |
RGD:6480464 |
CTD |
| G |
Cryaa |
crystallin, alpha A |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ctsd |
cathepsin D |
|
increases expression |
EXP |
1 |
202,619,669 |
202,631,545 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases activity |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
multiple interactions |
EXP |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
multiple interactions |
ISO |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
increases expression |
ISO |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Diablo |
diablo, IAP-binding mitochondrial protein |
|
affects localization |
ISO |
12 |
34,196,347 |
34,209,633 |
RGD:6480464 |
CTD |
| G |
Diablo |
diablo, IAP-binding mitochondrial protein |
|
affects localization |
ISO |
12 |
34,196,347 |
34,209,633 |
RGD:6480464 |
CTD |
| G |
Eif2a |
eukaryotic translation initiation factor 2A |
|
increases phosphorylation |
ISO |
2 |
147,870,265 |
147,903,411 |
RGD:6480464 |
CTD |
| G |
Eif2a |
eukaryotic translation initiation factor 2A |
|
multiple interactions |
ISO |
2 |
147,870,265 |
147,903,411 |
RGD:6480464 |
CTD |
| G |
Fmo1 |
flavin containing monooxygenase 1 |
|
increases expression |
EXP |
13 |
78,503,770 |
78,536,359 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
increases expression |
EXP |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gpx4 |
glutathione peroxidase 4 |
|
multiple interactions |
ISO |
7 |
11,162,521 |
11,165,318 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
multiple interactions |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Gusb |
glucuronidase, beta |
|
multiple interactions |
ISO |
12 |
27,744,409 |
27,757,755 |
RGD:6480464 |
CTD |
| G |
H2afx |
H2A histone family, member X |
|
multiple interactions |
ISO |
8 |
47,312,609 |
47,313,938 |
RGD:6480464 |
CTD |
| G |
Hal |
histidine ammonia lyase |
|
increases expression |
EXP |
7 |
30,520,913 |
30,551,145 |
RGD:6480464 |
CTD |
| G |
Hbg1 |
hemoglobin, gamma A |
|
increases expression |
ISO |
1 |
161,640,359 |
161,641,737 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
EXP |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
multiple interactions |
EXP |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
affects expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hp |
haptoglobin |
|
affects activity |
ISO |
19 |
39,443,016 |
39,447,566 |
RGD:6480464 |
CTD |
| G |
Hp |
haptoglobin |
|
multiple interactions |
ISO |
19 |
39,443,016 |
39,447,566 |
RGD:6480464 |
CTD |
| G |
Hspa1b |
heat shock protein 1B |
|
increases expression |
EXP |
20 |
3,955,274 |
3,957,748 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
EXP |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Lcat |
lecithin cholesterol acyltransferase |
|
multiple interactions |
EXP |
19 |
35,781,507 |
35,784,966 |
RGD:6480464 |
CTD |
| G |
Lcat |
lecithin cholesterol acyltransferase |
|
multiple interactions |
EXP |
19 |
35,781,507 |
35,784,966 |
RGD:6480464 |
CTD |
| G |
Ldha |
lactate dehydrogenase A |
|
multiple interactions |
EXP |
1 |
97,403,077 |
97,412,547 |
RGD:6480464 |
CTD |
| G |
Ldhb |
lactate dehydrogenase B |
|
multiple interactions |
EXP |
4 |
180,061,567 |
180,079,473 |
RGD:6480464 |
CTD |
| G |
LOC100360940 |
diablo-like |
|
affects localization |
ISO |
5 |
148,562,065 |
148,563,619 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
affects activity |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
affects activity |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
increases phosphorylation |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mb |
myoglobin |
|
multiple interactions |
EXP |
7 |
115,087,558 |
115,094,789 |
RGD:6480464 |
CTD |
| G |
Mbp |
myelin basic protein |
|
multiple interactions |
ISO |
18 |
78,943,608 |
79,057,329 |
RGD:6480464 |
CTD |
| G |
Mgat3 |
mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase |
|
increases expression |
EXP |
7 |
118,429,750 |
118,457,125 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
multiple interactions |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nefh |
neurofilament, heavy polypeptide |
|
increases expression |
EXP |
14 |
85,594,789 |
85,604,774 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
EXP |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
increases activity |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
EXP |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
ISO |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Ogdh |
oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) |
|
multiple interactions |
EXP |
14 |
87,022,994 |
87,090,768 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
increases expression |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
increases expression |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Park7 |
parkinson protein 7 |
|
multiple interactions |
ISO |
5 |
168,050,149 |
168,061,616 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pax3 |
paired box 3 |
|
multiple interactions |
ISO |
9 |
77,477,813 |
77,576,632 |
RGD:6480464 |
CTD |
| G |
Pax3 |
paired box 3 |
|
increases expression |
ISO |
9 |
77,477,813 |
77,576,632 |
RGD:6480464 |
CTD |
| G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 (soluble) |
|
decreases expression |
EXP |
3 |
164,012,410 |
164,018,359 |
RGD:6480464 |
CTD |
| G |
Pgk1 |
phosphoglycerate kinase 1 |
|
multiple interactions |
ISO |
X |
94,324,219 |
94,340,193 |
RGD:6480464 |
CTD |
| G |
Plg |
plasminogen |
|
multiple interactions |
ISO |
1 |
42,782,464 |
42,825,149 |
RGD:6480464 |
CTD |
| G |
Pltp |
phospholipid transfer protein |
|
decreases abundance |
ISO |
3 |
155,871,842 |
155,889,959 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases activity |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ppia |
peptidylprolyl isomerase A (cyclophilin A) |
|
increases expression |
EXP |
14 |
87,165,998 |
87,169,995 |
RGD:6480464 |
CTD |
| G |
Psmc6 |
proteasome (prosome, macropain) 26S subunit, ATPase, 6 |
|
multiple interactions |
ISO |
15 |
21,217,367 |
21,239,320 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases activity |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
affects localization |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rxra |
retinoid X receptor alpha |
|
multiple interactions |
ISO |
3 |
6,605,782 |
6,689,224 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
multiple interactions |
ISO |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Smad4 |
SMAD family member 4 |
|
multiple interactions |
ISO |
18 |
70,432,705 |
70,461,541 |
RGD:6480464 |
CTD |
| G |
Snca |
synuclein, alpha (non A4 component of amyloid precursor) |
|
multiple interactions |
ISO |
4 |
89,613,731 |
89,722,807 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
increases expression |
ISO |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
decreases expression |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
increases expression |
EXP |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Tert |
telomerase reverse transcriptase |
|
multiple interactions |
ISO |
1 |
30,445,180 |
30,465,942 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
decreases response to substance |
EXP |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases activity |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases expression |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
multiple interactions |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases response to substance |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
affects expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
increases expression |
ISO |
15 |
50,138,439 |
50,163,254 |
RGD:6480464 |
CTD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
multiple interactions |
ISO |
15 |
50,138,439 |
50,163,254 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
multiple interactions |
EXP |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Xbp1 |
X-box binding protein 1 |
|
increases expression |
ISO |
14 |
86,151,910 |
86,156,975 |
RGD:6480464 |
CTD |
Term paths to the root
|